DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07002905

CompletedPhase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity or Overweight With Weight-Related Comorbidities

Asset

ASC30

Oral · GLP-1 agonist

Listed sites

6

Recruiting sites

—

Enrollment

125

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Body weight

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07002905
Org study IDASC30-202

Timeline

Milestones

Study first posted2025-06-04actual
Study start2025-07-03actual
Primary completion2025-12-08actual
Study completion2025-12-08actual
Last update posted2025-12-15actual

Assets

Investigational agents

ASC30

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Have provided informed consent before initiation of any study-specific procedures.
•Male or female participants, non-smokers, between 18 and 75 years of age (both inclusive).
•No clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and other screening procedures.

Exclusion criteria

•Have evidence of any clinically significant active or chronic disease.
•Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or rare forms of diabetes mellitus.
•Have an autoimmune disease, is immunosuppressed or is in any way immunocompromised.
•Have a history of acute or chronic pancreatitis.
•Participants with a known clinically significant gastric emptying abnormality.
•Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy.
•Have a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the Investigator, may preclude the participant from following and completing the protocol.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
4
Safety / tolerability / PK
1

Weight & body composition

4 endpoints
Primary/protocol endpoint

Percent change in body weight from Baseline up to Week 13

Time frame:Baseline and Week 13

percent change from baseline, improvement

Secondary/protocol endpoint

Change in body weight (absolute) from Baseline up to Week 13

Time frame:Baseline and Week 13

change from baseline, improvement

Secondary/protocol endpoint

Change in waist circumference from Baseline up to Week 13

Time frame:Baseline and Week 13

change from baseline, improvement

Secondary/protocol endpoint

Change in body mass index from Baseline to Week 13

Time frame:Baseline and Week 13

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

Time frame:Baseline and Week 13

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.